ALEMBIC | SUN PHARMA | ALEMBIC/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 20.5 | 58.5 | 35.0% | View Chart |
P/BV | x | 0.8 | 4.3 | 17.9% | View Chart |
Dividend Yield | % | 0.3 | 0.9 | 32.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-21 |
SUN PHARMA Mar-21 |
ALEMBIC/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 123 | 654 | 18.8% | |
Low | Rs | 32 | 339 | 9.5% | |
Sales per share (Unadj.) | Rs | 2.9 | 139.6 | 2.1% | |
Earnings per share (Unadj.) | Rs | 0.5 | 9.5 | 5.7% | |
Cash flow per share (Unadj.) | Rs | 0.7 | 18.2 | 3.8% | |
Dividends per share (Unadj.) | Rs | 0.20 | 7.50 | 2.7% | |
Avg Dividend yield | % | 0.3 | 1.5 | 17.1% | |
Book value per share (Unadj.) | Rs | 89.5 | 193.6 | 46.2% | |
Shares outstanding (eoy) | m | 256.78 | 2,399.34 | 10.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 27.0 | 3.6 | 760.5% | |
Avg P/E ratio | x | 143.5 | 52.1 | 275.5% | |
P/CF ratio (eoy) | x | 111.7 | 27.3 | 409.7% | |
Price / Book Value ratio | x | 0.9 | 2.6 | 33.8% | |
Dividend payout | % | 37.1 | 78.8 | 47.1% | |
Avg Mkt Cap | Rs m | 19,868 | 1,190,430 | 1.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 226 | 68,622 | 0.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 735 | 334,981 | 0.2% | |
Other income | Rs m | 109 | 8,592 | 1.3% | |
Total revenues | Rs m | 844 | 343,573 | 0.2% | |
Gross profit | Rs m | 104 | 41,616 | 0.3% | |
Depreciation | Rs m | 39 | 20,800 | 0.2% | |
Interest | Rs m | 4 | 1,414 | 0.3% | |
Profit before tax | Rs m | 170 | 27,994 | 0.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 32 | 5,147 | 0.6% | |
Profit after tax | Rs m | 138 | 22,847 | 0.6% | |
Gross profit margin | % | 14.2 | 12.4 | 114.2% | |
Effective tax rate | % | 18.8 | 18.4 | 102.1% | |
Net profit margin | % | 18.8 | 6.8 | 276.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,021 | 304,421 | 0.3% | |
Current liabilities | Rs m | 594 | 161,456 | 0.4% | |
Net working cap to sales | % | 58.1 | 42.7 | 136.0% | |
Current ratio | x | 1.7 | 1.9 | 91.1% | |
Inventory Days | Days | 10,191 | 149 | 6,837.7% | |
Debtors Days | Days | 686 | 99 | 694.4% | |
Net fixed assets | Rs m | 23,069 | 336,682 | 6.9% | |
Share capital | Rs m | 514 | 2,399 | 21.4% | |
"Free" reserves | Rs m | 22,457 | 462,229 | 4.9% | |
Net worth | Rs m | 22,970 | 464,628 | 4.9% | |
Long term debt | Rs m | 0 | 8,981 | 0.0% | |
Total assets | Rs m | 24,090 | 641,103 | 3.8% | |
Interest coverage | x | 48.1 | 20.8 | 231.2% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0 | 0.5 | 5.8% | |
Return on assets | % | 0.6 | 3.8 | 15.6% | |
Return on equity | % | 0.6 | 4.9 | 12.3% | |
Return on capital | % | 0.8 | 6.2 | 12.2% | |
Exports to sales | % | 1.5 | 0 | - | |
Imports to sales | % | 6.1 | 0 | - | |
Exports (fob) | Rs m | 11 | NA | - | |
Imports (cif) | Rs m | 45 | NA | - | |
Fx inflow | Rs m | 11 | 84,493 | 0.0% | |
Fx outflow | Rs m | 45 | 30,334 | 0.1% | |
Net fx | Rs m | -34 | 54,159 | -0.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -22 | 61,704 | -0.0% | |
From Investments | Rs m | -347 | 5,362 | -6.5% | |
From Financial Activity | Rs m | -154 | -59,805 | 0.3% | |
Net Cashflow | Rs m | -523 | 5,964 | -8.8% |
Indian Promoters | % | 70.9 | 54.5 | 130.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 5.8 | 34.5 | 16.9% | |
FIIs | % | 1.1 | 14.4 | 7.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 29.1 | 45.5 | 64.0% | |
Shareholders | 80,135 | 662,384 | 12.1% | ||
Pledged promoter(s) holding | % | 0.0 | 5.6 | - |
Compare ALEMBIC With: CIPLA LUPIN DR. REDDYS LAB ZYDUS LIFESCIENCES AUROBINDO PHARMA
After opening the day on a choppy note, Indian share markets rallied as the session progressed and ended higher.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
Here's a rundown on Sun Pharma's June quarter results.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
In 2021, R&D of pharma companies roared to life in a never-before-seen way.
More Views on NewsThis aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
The good side of a market correction? Investors get consistent compounding stocks at a discount.
Why this may not be the best time to buy smallcaps.
These value stocks have the potential to deliver good returns in the long run. Watch out for them.
Global markets have become volatile, sending chills through the crude oil market.
More